Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

The market is wrong about $HIMS. $HIMS is moving towards a $PLTR-style, non-linear value creation even that brings the world's most valuable subscription service to the life.

Antonio Linares

117,219 subscribers

44,537 views • 6 months ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

biology<>AI is going to deliver most of the returns in the stock market I went long $pltr at $7, $amd at $4.2: this is way, way bigger breaks down into two buckets: read: $rxrx $naut $tem $cai $hims write: $ibrx $inkt $ngen $pbls most value accrues to the Ontology: $HIMS

biology<>AI is going to deliver most of the returns in the stock market I went long $pltr at $7, $amd at $4.2: this is way, way bigger breaks down into two buckets: read: $rxrx $naut $tem $cai $hims write: $ibrx $inkt $ngen $pbls most value accrues to the Ontology: $HIMS

Antonio Linares

77,485 views • 1 month ago

$HIMS is most likely the biggest disruption story the US has seen its history. No other company is positioned to disrupt the $4T US healthcare market like $HIMS. And as $HIMS gets bigger and stronger, legal friction will naturally increase.

$HIMS is most likely the biggest disruption story the US has seen its history. No other company is positioned to disrupt the $4T US healthcare market like $HIMS. And as $HIMS gets bigger and stronger, legal friction will naturally increase.

Antonio Linares

100,823 views • 1 year ago

Jeff Bezos says that if you have a 10% chance of making a 100x, you should take that bet every single time. This is the case with $HIMS. Down ~75% from its highs, ~$4B market cap, and a P/S ratio below 2. $HIMS trades as if it’s destined to fail — all the pessimism is already priced in. Once you realize $HIMS is not a GLP-1 company, but a platform, with new verticals launching faster and faster, it’s hard not to see $HIMS as the most asymmetric bet in the market.

Jeff Bezos says that if you have a 10% chance of making a 100x, you should take that bet every single time. This is the case with $HIMS. Down ~75% from its highs, ~$4B market cap, and a P/S ratio below 2. $HIMS trades as if it’s destined to fail — all the pessimism is already priced in. Once you realize $HIMS is not a GLP-1 company, but a platform, with new verticals launching faster and faster, it’s hard not to see $HIMS as the most asymmetric bet in the market.

Daniel

142,243 views • 6 months ago

$HIMS is tracking towards a $PLTR moment, as it turns longevity into a computation problem. It's going to understand exactly what is happening inside the body of any subscriber at the molecular level and fix illness before it even happens.

$HIMS is tracking towards a $PLTR moment, as it turns longevity into a computation problem. It's going to understand exactly what is happening inside the body of any subscriber at the molecular level and fix illness before it even happens.

Antonio Linares

34,960 views • 9 months ago

The decision by $LLY and $NVO to offer their drugs on $HIMS proves the power of its platform. $HIMS is like $AMZN and $NFLX in the early stages. The vision of Andrew Dudum is taking shape. Over time, more drugs will be added to the platform. The reason is simple: with 2.5M subscribers, $HIMS has built the largest health distribution platform in the world. If you want maximum reach, you go where the users are. That’s $HIMS. At a $6B market cap, $HIMS remains one of the biggest opportunities in the market.

The decision by $LLY and $NVO to offer their drugs on $HIMS proves the power of its platform. $HIMS is like $AMZN and $NFLX in the early stages. The vision of Andrew Dudum is taking shape. Over time, more drugs will be added to the platform. The reason is simple: with 2.5M subscribers, $HIMS has built the largest health distribution platform in the world. If you want maximum reach, you go where the users are. That’s $HIMS. At a $6B market cap, $HIMS remains one of the biggest opportunities in the market.

Daniel

51,442 views • 3 months ago

everyone gave up on $HIMS in february 2026 the stock is up ~3X since $hims is a not a GLP-1 company, but a Healthcare Ontology $2,000/share intrinsic value by the year 2030

everyone gave up on $HIMS in february 2026 the stock is up ~3X since $hims is a not a GLP-1 company, but a Healthcare Ontology $2,000/share intrinsic value by the year 2030

Antonio Linares

104,041 views • 1 month ago

My reply to Joseph Carlson, about the proof of my $AMD, $TSLA, $PLTR, $SPOT and $HIMS extraordinarily succesful picks.

My reply to Joseph Carlson, about the proof of my $AMD, $TSLA, $PLTR, $SPOT and $HIMS extraordinarily succesful picks.

Antonio Linares

479,836 views • 1 year ago

Shared this in the Discord yesterday and I figured it would be a valuable tool for everyone to use. Understanding how to use Finviz for scanning the market and looking for names with momentum. Reshare if you find it valuable 🙏 $HOOD $PLTR $QBTS $EQT $KGC $HIMS $SEZL

Shared this in the Discord yesterday and I figured it would be a valuable tool for everyone to use. Understanding how to use Finviz for scanning the market and looking for names with momentum. Reshare if you find it valuable 🙏 $HOOD $PLTR $QBTS $EQT $KGC $HIMS $SEZL

RealSimpleAriel

45,011 views • 1 year ago

$HIMS is about to trigger the biggest healthcare shift in 100 years

$HIMS is about to trigger the biggest healthcare shift in 100 years

Antonio Linares

30,380 views • 8 months ago

everyone gave up on $hims in february 2026 the stock is up ~3x since $hims isn’t a glp-1 company. it’s a healthcare ontology. $2,000/share intrinsic value by 2030

everyone gave up on $hims in february 2026 the stock is up ~3x since $hims isn’t a glp-1 company. it’s a healthcare ontology. $2,000/share intrinsic value by 2030

Antonio Linares

53,475 views • 1 month ago

$RBLX is a Singularity Scaler: much like $PLTR, $DUOL and $HIMS, its earning power is likely to increase exponentially, in tandem with the evolution of AI models.

$RBLX is a Singularity Scaler: much like $PLTR, $DUOL and $HIMS, its earning power is likely to increase exponentially, in tandem with the evolution of AI models.

Antonio Linares

31,383 views • 1 year ago

This Stock is Next to make NEW$millionaires‼️ "the MOVE will SHOCK the market" $HIMS $AMD $MU $NFLX $CELH

This Stock is Next to make NEW$millionaires‼️ "the MOVE will SHOCK the market" $HIMS $AMD $MU $NFLX $CELH

Jeremy Lefebvre

50,624 views • 2 days ago

$hims dropped 50%+ four times in 2025. the stock is down 80% from the highs. this stock has broken most investors. meanwhile, this is who real long-term $hims holders have become:

$hims dropped 50%+ four times in 2025. the stock is down 80% from the highs. this stock has broken most investors. meanwhile, this is who real long-term $hims holders have become:

Antonio Linares

38,154 views • 4 months ago

$hims is back at pre lawsuit levels. the bear case has nothing left. $nvo is now a key partner. peptides are going mainstream, and $hims is the largest healthcare d2c platform on earth, the only one with a verticalised peptide supply chain. $hims here is $amd at $75 last year.

$hims is back at pre lawsuit levels. the bear case has nothing left. $nvo is now a key partner. peptides are going mainstream, and $hims is the largest healthcare d2c platform on earth, the only one with a verticalised peptide supply chain. $hims here is $amd at $75 last year.

Antonio Linares

64,503 views • 16 days ago

$NVO closed the deal with $HIMS because: 1. They had to. 2. And/or they make more money via $HIMS. This is the start of a much bigger trend, in which $HIMS likely becomes the go-to distributor of Big Pharma companies for the 21st century consumer.

$NVO closed the deal with $HIMS because: 1. They had to. 2. And/or they make more money via $HIMS. This is the start of a much bigger trend, in which $HIMS likely becomes the go-to distributor of Big Pharma companies for the 21st century consumer.

Antonio Linares

72,551 views • 1 year ago

$HIMS Over 100+ requests for me to update $HIMS. Here's the exact video on when to buy and what to expect moving forward. Short-term might be ugly. Long-term will (most likely) head to all-time highs.

$HIMS Over 100+ requests for me to update $HIMS. Here's the exact video on when to buy and what to expect moving forward. Short-term might be ugly. Long-term will (most likely) head to all-time highs.

StockWhale

66,590 views • 1 year ago

Chinese media : Jeon Jungkook BTS is the most valuable "Korea's Shi Yong Yi" or the most valuable korean man with title forever number 1 in the world or world's eternal 1st. His life story is so incredible that even novelists wouldn't dare to write it. #JUNGKOOK #전정국

Chinese media : Jeon Jungkook BTS is the most valuable "Korea's Shi Yong Yi" or the most valuable korean man with title forever number 1 in the world or world's eternal 1st. His life story is so incredible that even novelists wouldn't dare to write it. #JUNGKOOK #전정국

Maddie 💟 XIAO ZHAN IS FREE

27,026 views • 9 months ago

🚨 TBPN TALKING ABOUT $HIMS CEO ANDREW DUDUM John Coogan: "Who's the most underrated (or greatest) entrepreneur of all-time?" Nate Bosshard: "In the last decade, Andrew Dudum of Hims & Hers. Fastest consumer company to go public. The only successful consumer SPAC trading at $11B. HE IS AN ABSOLUTE KILLER. He is incredibly underrated."

🚨 TBPN TALKING ABOUT $HIMS CEO ANDREW DUDUM John Coogan: "Who's the most underrated (or greatest) entrepreneur of all-time?" Nate Bosshard: "In the last decade, Andrew Dudum of Hims & Hers. Fastest consumer company to go public. The only successful consumer SPAC trading at $11B. HE IS AN ABSOLUTE KILLER. He is incredibly underrated."

Hims House

29,917 views • 11 months ago